Hangzhou Tigermed Consulting Co., Ltd.
HNGZY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $248 | $1,686 | $1,564 | $1,536 |
| % Growth | -85.3% | 7.8% | 1.9% | – |
| Cost of Goods Sold | $180 | $1,178 | $1,094 | $1,264 |
| Gross Profit | $68 | $508 | $470 | $272 |
| % Margin | 27.5% | 30.1% | 30% | 17.7% |
| R&D Expenses | $9 | $68 | $59 | $66 |
| G&A Expenses | $0 | -$67 | $180 | -$258 |
| SG&A Expenses | $34 | -$91 | $229 | -$354 |
| Sales & Mktg Exp. | $0 | -$24 | $49 | -$96 |
| Other Operating Expenses | $1 | $232 | $37 | $980 |
| Operating Expenses | $45 | $208 | $325 | $692 |
| Operating Income | $23 | $300 | $145 | -$421 |
| % Margin | 9.5% | 17.8% | 9.2% | -27.4% |
| Other Income/Exp. Net | $86 | -$1 | -$1 | -$2 |
| Pre-Tax Income | $109 | $299 | $144 | -$423 |
| Tax Expense | $7 | $46 | $34 | $33 |
| Net Income | $89 | $218 | $165 | -$408 |
| % Margin | 35.9% | 12.9% | 10.6% | -26.6% |
| EPS | 0.1 | 0.25 | 0.19 | -0.47 |
| % Growth | -60% | 31.6% | 140.4% | – |
| EPS Diluted | 0.1 | 0.25 | 0.19 | -0.47 |
| Weighted Avg Shares Out | 861 | 871 | 871 | 862 |
| Weighted Avg Shares Out Dil | 861 | 871 | 871 | 862 |
| Supplemental Information | – | – | – | – |
| Interest Income | $29 | $0 | $0 | $0 |
| Interest Expense | $2 | $17 | $32 | $25 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $111 | $310 | $187 | -$288 |
| % Margin | 44.7% | 18.4% | 12% | -18.8% |